Astrazeneca PharQ2 FY20

Astrazeneca Phar Q2 FY20 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6,168P/E: 81.9Market Cap: ₹15.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

  • Calquence has generated $173 million in worldwide sales since its launch in November 2017. (Page 22)
  • There are ongoing Phase III trials and regulatory submissions expected to expand indications and markets, including:
  • - ACE-CL-309 ASCEND in relapsed/refractory CLL (Approved in US)
  • - ACE-CL-007 ELEVATE TN in previously-untreated CLL (Approved in US)
  • - Calquence regulatory submissions in EU and Japan targeted for H1 2020
  • - ACE-CL-006 ELEVATE RR in relapsed/refractory high-risk CLL with data expected 2021+
  • - ACE CL-311 for previously-untreated CLL (with venetoclax) with data expected 2021+
  • Approximately 28,000 total patients in the US and EU treated or eligible (17,000 front-line; 11,000 relapsed/refractory). (Page 22)
  • Positive Phase III data readouts in CLL create momentum for future growth.

See what Astrazeneca Phar management said on margin guidance — free account, 30 seconds.

Fundraise plans

The provided document (310.pdf) does not contain any information regarding current or future fundraising efforts by AstraZeneca through debt or equity. The content mainly focuses on: - Clinical trial data and updates for Calquence in CLL (chronic lymphocytic leukemia) - Safety and efficacy results from the Phase III ELEVATE TN trial - Presentation and conference call use restrictions - Forward-looking statements caution - Company sales figures and trial status updates No sections mention plans or activities related to raising capital via debt or equity issuance.

See what Astrazeneca Phar management said on order book — free account, 30 seconds.

Capex plans

The provided pages of the AstraZeneca ASH 2019 presentation (310.pdf) do not explicitly mention any current or future capital expenditure (capex), capital investments, or strategic investments. The focus is mainly on: - Clinical trial updates for Calquence in CLL (ELEVATE TN, ASCEND trials). - Product pipeline progress including new agents (AZD5991, AZD4573, AZD2811, AZD0466). - Regulatory submissions planned in H1 2020. - Sales performance and patient numbers. - Safety and efficacy data from trials. - Forward-looking statements highlighting general risks but no specific capex plans. No direct references to capex, capital investment plans, or strategic investments are detailed in the provided content.

Track Astrazeneca Phar — get its next earnings analysis in your feed

How does Astrazeneca Phar rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAstrazeneca Phar

How does Astrazeneca Phar rank in Pharmaceuticals & Biotechnology?

Compare Astrazeneca Phar against every Pharmaceuticals & Biotechnology company (Q2 FY20) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →